文献速递细菌感染、耐药与抗菌药物

连续临床分离株抗菌药物敏感性短期稳定性及重复检测策略

How stable are antimicrobial susceptibility profiles in serial clinical isolates? A retrospective study informing repeat-testing strategies.
PubMed 文献 · Clin Microbiol Infect · 2026-07-20

多数菌种-药物组合分类一致率超过90%,耐药转变多低于5%,但铜绿假单胞菌、阴沟肠杆菌复合群及凝固酶阴性葡萄球菌部分药物不稳定率较高,支持基于菌种和标本类型的限制性转诊策略。

要点

  • 7天内多数菌种药敏稳定,分类一致率超90%
  • 铜绿假单胞菌对哌拉西林-他唑巴坦耐药转变最高达13.9%
  • 跨标本类型比较变异性略高于同标本类型

核心结论

  • 连续临床分离株抗菌药物敏感性在7天内对多数菌种高度稳定。
  • 基于菌种和标本类型的保守重复检测策略可安全减少不必要的药敏试验。

主要发现

  • 多数菌种-药物组合分类一致率超过90%。
  • 多数肠杆菌目和金黄色葡萄球菌耐药转变低于5%。
  • 铜绿假单胞菌对哌拉西林-他唑巴坦耐药转变高达13.9%,阴沟肠杆菌复合群达9%。
  • 凝固酶阴性葡萄球菌对氟氯西林耐药转变高达11%。
  • 跨标本类型比较变异性略高于同标本类型分析。

关键数值与推荐

  • 临床相关变化定义为转变为耐药。
  • 为考虑分析变异性,伴随≥2倍MIC升高的转变单独分析。
  • 不稳定性模式整合为风险分层的药敏转诊框架。

临床怎么用

  • 对多数菌种7天内可参考先前药敏结果,减少重复检测。
  • 对铜绿假单胞菌、阴沟肠杆菌复合群和凝固酶阴性葡萄球菌应谨慎省略重复检测。
  • 可基于菌种和标本类型实施限制性药敏转诊策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Repeat antimicrobial susceptibility testing is frequently performed whenever the same bacterial species is repeatedly isolated from hospitalized patients, consuming considerable laboratory resources. Although referral to prior antimicrobial susceptibility testing (AST) results may reduce laboratory workload, evidence guiding safe omission of repeat testing is limited. Therefore, we aimed to quantify short-term stability of antimicrobial susceptibility in serial clinical isolates within 7 days and to derive an evidence-informed repeat-testing strategy. METHODS: We conducted a retrospective observational study using routine AST data generated in July 2023-October 2025 with the BD Phoenix™ M50 system. Serial AST results from the same patient and species were compared within a 7-day interval, both within and across-specimen types. Evaluated antibiotics reflected local and national reporting and treatment guidelines. Clinically relevant changes were defined as transitions to resistant. To account for analytical variability, transitions accompanied by ≥2 twofold MIC increases were separately analysed. Instability patterns were integrated into a risk-stratified AST referral framework. RESULTS: A total of 11 831 repeat comparisons across 12 bacterial species were included. Overall categorical agreement exceeded 90% for most organism-antibiotic combinations. Transitions to resistance remained below 5% for most Enterobacterales and Staphylococcus aureus. Higher instability was observed for Pseudomonas aeruginosa and Enterobacter cloacae complex, particularly for β-lactam/β-lactamase inhibitor combinations such as piperacillin-tazobactam (up to 13.9% and 9%, respectively) as well as for coagulase-negative staphylococci, e.g. for flucloxacillin (up to 11%). Across-specimen comparisons demonstrated slightly higher variability than within-specimen analyses, thereby supporting specimen-restricted referral strategies which were based on integrating quantitative instability thresholds with clinical risk considerations. CONCLUSIONS: Antimicrobial susceptibility of serial clinical isolates remains highly stable within 7 days for most species. A conservative species- and specimen-restricted repeat-testing strategy may safely reduce unnecessary AST while preserving detection of clinically relevant resistance. These findings support the implementation of evidence-informed AST referral policies in clinical microbiology laboratories.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Godelaine J, Dingemans J, Hilkens P, et al. How stable are antimicrobial susceptibility profiles in serial clinical isolates? A retrospective study informing repeat-testing strategies. Clin Microbiol Infect. 2026. PMID: 42398659. doi:10.1016/j.cmi.2026.06.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。